Evidence map›Paper›PMID 26828202›Full record

ArticlePLoS pathogens2016

A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells.

Zachary B Davis, Andrew Cogswell, Hamish Scott, Amanda Mertsching, Julie Boucau, Daniel Wambua, Sylvie Le Gall, Vicente Planelles, Kerry S Campbell, Edward Barker

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. CD56bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNA.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  18. Review
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Zachary B DavisDepartment of Immunology/Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Andrew CogswellDepartment of Immunology/Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Hamish ScottDivision of Infection and Immunity and Cell Signaling and Cell Death, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Amanda MertschingDepartment of Immunology/Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Julie BoucauRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Daniel WambuaRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Sylvie Le GallRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Vicente PlanellesDepartment of Pathology, University of Utah, Salt Lake City, Utah, United States of America.
Kerry S CampbellFox Chase Cancer Center, Institute for Cancer Research, Philadelphia, Pennsylvania, United States of America.
Edward BarkerDepartment of Immunology/Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Rush University Medical Center · USRagon Institute of MGH, MIT and Harvard · USFox Chase Cancer Center · USUniversity of Utah · USWalter and Eliza Hall Institute of Medical Research · AU

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LUCIW, PAUL · 2011 to 2015
$39.5M
Negative Signalling by Killer Ig-like ReceptorsR01CA083859 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CAMPBELL, KERRY S · 2000 to 2014
$3.8M
Vpu inhibits NK cell function through down regulation of NTB-AR01AI065361 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI BARKER, EDWARD · 2006 to 2016
$2.9M
Learning from attenuated CMV how to broaden HIV-specific T cell responsesR01AI112493 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LE GALL, SYLVIE · 2014 to 2017
$2.2M
Modulation of surface markers by HIV-1 Vpu/Vpr and sensitivity to NK cell lysisR21AI081681 · NIAID · UNIVERSITY OF UTAH · PI BARKER, EDWARD, PLANELLES, VICENTE · 2009 to 2010
$423k
HIV Evasion of NK Cells in Lymph NodesR21AI078749 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI BARKER, EDWARD, TENORIO, ALLAN R · 2009 to 2010
$415k
NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA083859NIAID NIH HHS HHSN272201300006CNIAID NIH HHS R01 AI065361NIAID NIH HHS R01 AI112493NIAID NIH HHS R21 AI078749NIAID NIH HHS R21AI078749NIAID NIH HHS R21 AI081681NIAID NIH HHS U19 AI096113NIAID NIH HHS U19AI096113
6 · The paper itself

Abstract

Major histocompatibility class I (MHC-I)-specific inhibitory receptors on natural killer (NK) cells (iNKRs) tolerize mature NK cell responses toward normal cells. NK cells generate cytolytic responses to virus-infected or malignant target cells with altered or decreased MHC-I surface expression due to the loss of tolerizing ligands. The NKG2A/CD94 iNKR suppresses NK cell responses through recognition of the non-classical MHC-I, HLA-E. We used HIV-infected primary T-cells as targets in an in vitro cytolytic assay with autologous NK cells from healthy donors. In these experiments, primary NKG2A/CD94(+) NK cells surprisingly generated the most efficient responses toward HIV-infected T-cells, despite high HLA-E expression on the infected targets. Since certain MHC-I-presented peptides can alter recognition by iNKRs, we hypothesized that HIV-1-derived peptides presented by HLA-E on infected cells may block engagement with NKG2A/CD94, thereby engendering susceptibility to NKG2A/CD94(+) NK cells. We demonstrate that HLA-E is capable of presenting a highly conserved peptide from HIV-1 capsid (AISPRTLNA) that is not recognized by NKG2A/CD94. We further confirmed that HLA-C expressed on HIV-infected cells restricts attack by KIR2DL(+) CD56(dim) NK cells, in contrast to the efficient responses by CD56(bright) NK cells, which express predominantly NKG2A/CD94 and lack KIR2DLs. These findings are important since the use of NK cells was recently proposed to treat latently HIV-1-infected patients in combination with latency reversing agents. Our results provide a mechanistic basis to guide these future clinical studies, suggesting that ex vivo-expanded NKG2A/CD94(+) KIR2DL(-) NK cells may be uniquely beneficial.

Indexed as

Histocompatibility Antigens Class IHIV-1HIV InfectionsHLA-C AntigensHLA-E AntigensHumansKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily DPeptidesReceptors, Natural Killer CellT-LymphocytesHistocompatibility Antigens Class IHLA-C AntigensHLA-E AntigensNK Cell Lectin-Like Receptor Subfamily DPeptidesReceptors, Natural Killer Cell

Identifiers

PMID26828202
PMCPMC4735451
OpenAlexW2266873158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.